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Abstract:  
Objectives  
To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs 
syndrome (RLS) and the evolution of EDS under different RLS therapies.  
Methods  
We analyzed data from the “Swiss RLS” study, which was conducted to compare treatment 
efficacy and safety of the dopamine agonist pramipexole (PPX) versus levodopa/ benserazide 
(L/B) in de novo patients with idiopathic RLS and was performed as a randomized, double-
dummy, comparative crossover trial. Primary outcome measure of the present study was the 
change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There 
were thirty- seven patients (21 women) included, mean age was 56.6 (range 25-85), mean 
body-mass-index was 24.6 (+/-3.5 SD).    
Results  
At baseline, EDS (as determined by an ESS score >10), was found in 32% of the patients. 
Sleepy RLS patients were younger (p<0.001) than non-sleepy patients. PPX and L/B both 
were effective in the treatment of RLS symptoms (IRLS score, p<0.001 and p=0.002). Overall 
ESS was reduced (main effect for “time”, p=0.02) independent from the dopaminergic 
substance. In 5/37 patients ESS score deteriorated to >10 under treatment (PPX=3 patients, 
L/B=2 patients). No sleep attacks occurred.   
Conclusions: 
Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually 
promotes wakefulness, but infrequently leads to daytime sleepiness.    
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Introduction: 
Restless legs syndrome (RLS) is a frequent neurological disorder and one of the most 
common sleep disorders. Four essential criteria are obligatory for the clinical diagnosis. These 
criteria were established, and revised, by the International RLS Study Group.1 Due to RLS 
symptoms and/or PLM initiating and maintaining sleep is often complicated and disrupted. 
Whereas insomnia is a common complain in RLS little is known about the existence of 
excessive daytime sleepiness (EDS). In a few studies2-4 a subpopulation of RLS patients with 
daytime sleepiness (Epworth sleepiness scale [ESS]5 score >10) has been identified. 
Pathophysiology and predictors of EDS in RLS still remain unclear and there is little 
information on the evolution of EDS under different RLS therapies.6-8 Occasionally, sleep 
attacks are reported under dopaminergic treatment in Parkinson’s disease and RLS patients.7  
Hence we analyzed data from the Swiss RLS (SRLS) trial (Bassetti et al., submitted), a 
randomized double-blind two-sequence, two-period crossover study which was conducted to 
determine the hypothesis of non-inferiority of pramipexole compared to dual-release,9 a 
combination of immediate- and slow-release, levodopa/benserazide (L/B) in the short-term 
treatment of RLS, in order to assess frequency and characteristics of RLS patients with EDS 
and to evaluate the course of EDS under adequate treatment with pramipexole (PPX) or L/B.  
 
Material and Methods:  
Ethical aspects 
The protocol, patient information and informed consent has been reviewed and approved by 
the Institutional Review Boards (IRB) and has been notified to the Swiss Health Authority.  
Study design  
We analyzed data from the SRLS study. This study was conducted to compare non-inferiority 
of pramipexole versus levodopa in the treatment efficacy of RLS symptoms and PLM-S as 
multi-center, randomized, double-blind, comparative crossover trial with two treatment 
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periods of each four weeks. After treatment period 1 with either PPX or L/B, patients were 
switched to the respective other treatment (period 2). Cross-over washout period between 
treatments lasted two weeks. 
Medication  
PPX 0.25-0.75 mg (Mirapex/ Sifrol®) and dual-release L/B 125-375 mg (Madopar® DR) were 
administered orally, once daily before bedtime. Drug exposure for each period was 26 to 30 
days, the washout period in between treatment periods lasted 2 weeks. There was no evidence 
of any carry-over effect.  
Patient population 
Patients aged 25 to 85 years, fulfilling all clinical criteria for diagnosis of idiopathic RLS, 
presenting RLS symptoms almost every day and with more than five PLM/h during bedtime 
were included. Patients previously treated with PPX, L/B or another DA, significant diseases 
other than restless legs syndrome, in particular other sleep-wake disorders, were excluded.  
Outcome measures 
Primary endpoint of the present study was the change in ESS score under treatment. 
Secondary outcome measures were efficacy in changes of RLS-score, PLMS index, sleep 
quality, and Hospital Anxiety and Depression Scale (HAD). PLMS index was determined 
using The PAM-RL Monitor System (IM Systems, Baltimore, USA). 10 
Statistics 
We analyzed data from 37 patients (21 women) with a complete data set. Excessive daytime 
sleepiness was defined as an ESS score >10. Statistical analysis was performed using SPSS 
software package version 14, SPSS Inc., Chicago, IL. Significant changes of ESS and IRLS 
under different treatments were estimated by 2-way and 3-way repeated measures analysis of 
variance (rANOVA, general linear model) with the between-subject factors treatment 
(pramipexole vs. levodopa), group (sleepy vs. non-sleepy patients) and the within factor time 
(baseline- end) followed by post-hoc t-tests.  The chi-square and Student t-tests were used to 
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analyze categorical and continuous variables. Pearson’s product correlations were performed 
to identify correlations between the individual items. Significance was determined as p≤0.05. 
All results are expressed as mean ( standard deviation). 
Results:  
See Figure 1 
Daytime sleepiness   
Period 1: We found an ESS >10 (mean 13.3  2.1) in 12 (32%) and severe EDS, as 
determined by an ESS >14 in 5 (14% of all 37) patients. ESS was reduced with treatment in 
sleepy and non-sleep patients (main effect for “time” (F 1/33= 6.63 p=0.02) independent from 
substance (period x treatment interaction: F 1/33=0.5, p=0.82). Triple interaction however 
revealed that the effect of treatment differed among the two groups (time x group x treatment 
interaction: F 1/33=4.3, p=0.05). In sleepy patients, pramipexole significantly improved ESS 
from 14.3  2.3 to 10.5  5.2 (n=6, p=0.05), whereas under levodopa treatment ESS only 
slightly improved and statistically not significant from 12.3  1.5 to 11  2.8 (n=6, n.s.). In 
the non-sleepy patients, ESS did not significantly change (PPX: from 7.4  2.2 to 8.1  2.9, 
and L/B: from 6.0  2.8 to 4.7  1.6, respectively).  
Under PPX (L/B) therapy in three (two) out of all 37 patients, ESS score deteriorated to a 
score >10. Nevertheless RLS symptoms (IRLS and PLMS) improved in these patients. No 
sleep attack occurred.  
Period 2: We found 11 (30%) patients with ESS >10 (mean 12.5  1.4) and one patient with 
ESS >14. In (all) sleepy patients, ESS improved under therapy (12.6  1.4 to 11.2  2.9, 
p=0.07). Taking in account the different medications used, again there was no significant 
change of ESS under levodopa treatment 12.6  1.6 to 12  3 (n=8, n.s.) whereas in PPX there 
was an improvement of ESS from 12.3  1.2 to 9  2. Due to a too small number (n=3) of 
sleepy patients treated with pramipexole no statistical analysis was performed.  
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Differences and correlations: Sleepy RLS patients were younger than non-sleepy RLS patients 
(50.4  7.5 versus 59.6  11.6, p=0.007). No other statistical differences or correlations in 
gender, body mass index (BMI), medication, IRLS-score, depression, anxiety, or PLMS- 
Index were found between sleepy and non-sleepy RLS patients. For further details please see 
Table 1.  None of the evaluated factors was able to predict the development of new sleepiness 
(on ESS).  
Restless legs symptoms  
Period 1: IRLS improved within period 1 (main effect of time: F 1/33=21.3, p=0.001) with 
either medication (no time x treatment interaction F1/33 = 0.1, p=0.9). Post hoc t-test confirmed 
that mean IRLS score of the 37 patients at baseline, was 22.8  6.9 and improved to a mean of 
15.4  8.2 (p<0.001) under treatment with levodopa (n=17) or pramipexole (n=20).   
The effect of pramipexole and levodopa on IRLS was quiet similar in sleepy and non-sleepy 
patients (time x group x treatment interaction: F 1/33=1.45, p=0.24). See Table 1. 
Period 2: After cross-over at baseline of treatment period 2 mean IRLS for all patients was 
18.8 ( 7.8) and improved to 15.3 ( 8.4), p=0.03.  
 
Discussion:  
To our best knowledge, this is the first study which tested for the evolution of EDS under two 
different dopaminergic RLS therapies (pramipexole and levodopa) in adequate dosing.  
Among idiopathic RLS patients, EDS is estimated in a subgroup of 20-30%.2-4 Our result of 
32% (period 1) and 30% (period 2), respectively, of sleepy RLS patients therefore is in line 
with previous studies.  
From our results we could not identify major predictors of sleepiness in RLS patients. Sleepy 
RLS patients were younger, confirming the previous result of Bassetti et al.3 Besides of this, 
no statistical differences in respect to gender, severity of RLS (IRLS-score), body mass index 
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(BMI), medication, depression, anxiety, or PLMS- Index were found when compared sleepy 
with non-sleepy patients.  
Pramipexole and levodopa are both effective in the treatment of RLS symptoms.  
Overall ESS was reduced under dopaminergic treatment, mainly due to the reduction in 
sleepy patients. This finding is in contrast to Parkinson´s disease, where dopamine therapy 
often leads to daytime sleepiness. This difference is possibly due to different dosages and time 
of administration of the drugs.  
Both treatments were of similar effect in the reduction of ESS with a trend in favor of PPX. 
Nevertheless in some patients ESS deteriorated and few patients became sleepy (ESS>10). 
This was the case for both treatments. 
We assume that dopaminergic dysfunction is directly involved in excessive daytime 
sleepiness in RLS-patients. A dopaminergic dysfunction has also been suggested to be 
involved in EDS of other sleep disorders. Neurochemical studies have shown changes in 
dopamine metabolites concentrations in the CSF of patients with idiopathic hypersomnia (IH) 
and in patients with narcolepsy (N) suggesting an increased turnover or impaired dopamine 
release.11 Modafinil, a wakefulness-promoting drug, may increase wakefulness through 
activation of noradrenergic and dopaminergic systems.12 We hypothesize a dopaminergic 
dysfunction/ deficiency in sleepy RLS patients that differs from the pathophysiology of non-
sleepy RLS patients, the exact mechanism of dopaminergic transmission affected in sleepy 
RLS patients however remains unclear. The different effects of levodopa and 
dopaminagonists on EDS however corroborate our assumption that the dopaminergic system 
has distinctive effects.  
We are aware of the limitations of our study: analyses were done with only a small number of 
patients and the design of the study was done to evaluate treatment efficacy / non-inferiority 
of two treatments and not primary to evaluate excessive daytime sleepiness in RLS. Due to 
small numbers no intra-individual comparison after cross-over could be realized.  
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Further studies with greater populations including objective measurements (e.g. Multiple 
Sleep Latency Test) on sleepiness are needed to confirm our results.  
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Figure legends 
Figure 1: ESS distribution and evolution under dopaminergic treatment (treatment periods 1 
and 2) 
Table 1 Baseline PLMS index, demographic and clinical characteristics in RLS patients 
with and without excessive daytime sleepiness  
 
    non-sleepy (ESS ≤10) sleepy (ESS >10) p-value 
 
n (%)    25 (68%)   12 (32%)  
age [y]    59.6 (±11.6)   50.4 (±7.5)  0.007 
female sex, n (%)  14 (56%)   7 (58%)  N.S. 
BMI    24.7 (±3.7)   24.5 (±3.5)  N.S.  
IRLS score    23 (±5.8)   22.7 (±6.9)  N.S. 
PLM-S [ /h]   21.3 (±14.6)   20.9 (±14.6)  N.S. 
HADS, subscale anxiety  8.5 (±2.2)   8.6 (±2.3)  N.S. 
HADS, subscale depression 11.3 (±1.3)   11.3 (±1.6)  N.S.  
 
All results are expressed as mean ( standard deviation). 
 
ESS: Epworth Sleepiness Scale  
BMI: Body-Mass-Index [kg/m2] 
IRLS: International RLS Study Group Rating Scale  
PLM-S: Periodic Leg Movements in Sleep  
HADS: Hospital Anxiety and Depression Scale  
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